nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

25.01.2016 | Review

Manipulation of BCG vaccine: a double-edged sword

verfasst von: V. K. Singh, R. Srivastava, B. S. Srivastava

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Mycobacterium bovis Bacillus Calmette–Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach.

Bloom BR, Murray CJ (1992) Tuberculosis: commentary on a reemergent killer. Science 57:1055–1064CrossRef

Sakula A (1983) BCG: who were Calmette and Guérin? Thorax 38:806–812PubMedPubMedCentralCrossRef

Brosch R, Gordon SV, Pym A, Eiglmeier K, Garnier T, Cole ST (2000) Comparative genomics of the mycobacteria. Int J Med Microbiol 290:143–152. doi:10.1016/S1438-4221(00)80083-1 PubMedCrossRef

Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544. doi:10.1038/31159 PubMedCrossRef

Joung SM, Ryoo S (2013) BCG vaccine in Korea. Clin Exp Vaccine Res 2:83–91. doi:10.7774/cevr.2013.2.2.83 PubMedPubMedCentralCrossRef

Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S et al (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520–1523PubMedCrossRef

Tripathy SP (1983) The case for B.C.G. Ann Natl Acad Med Sci 19:11–21PubMed

da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP (2014) Recombinant BCG: innovations on an Old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 5:152. doi:10.3389/fimmu.2014.00152 PubMedPubMedCentralCrossRef

Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393–422. doi:10.1146/annurev.immunol.021908.132703 PubMedPubMedCentralCrossRef

10.

Pearl JE, Torrado E, Tighe M, Fountain JJ, Solache A, Strutt T et al (2012) Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection. Eur J Immunol 42:3267–3279. doi:10.1002/eji.201142158 PubMedPubMedCentralCrossRef

11.

Geldmacher C, Zumla A, Hoelscher M (2012) Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS 7:268–275. doi:10.1097/COH.0b013e3283524e32 PubMed

12.

O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR (2013) The immune response in tuberculosis. Annu Rev Immunol 31:475–527. doi:10.1146/annurev-immunol-032712-095939 PubMedCrossRef

13.

Robinson RT, Orme IM, Cooper AM (2015) The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression. Immunol Rev 264:46–59. doi:10.1111/imr.12259 PubMedCrossRef

14.

Schlesinger LS (1996) Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Curr Top Microbiol Immunol 215:71–96PubMed

15.

Eum S-Y, Kong J-H, Hong M-S, Lee Y-J, Kim J-H, Hwang S-H et al (2010) Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122–128. doi:10.1378/chest.09-0903 PubMedPubMedCentralCrossRef

16.

Wolf AJ, Linas B, Trevejo-Nuñez GJ, Kincaid E, Tamura T, Takatsu K et al (2007) Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 179:2509–2519PubMedCrossRef

17.

Bhatt K, Salgame P (2007) Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 27:347–362. doi:10.1007/s10875-007-9084-0 PubMedCrossRef

18.

Chen M, Gan H, Remold HG (2006) A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol 176:3707–3716PubMedCrossRef

19.

Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:93–129. doi:10.1146/annurev.immunol.19.1.93 PubMedCrossRef

20.

Chen M, Divangahi M, Gan H, Shin DSJ, Hong S, Lee DM et al (2008) Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205:2791–2801. doi:10.1084/jem.20080767 PubMedPubMedCentralCrossRef

21.

Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM et al (2009) Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 10:899–906. doi:10.1038/ni.1758 PubMedPubMedCentralCrossRef

22.

Behar SM, Divangahi M, Remold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 8:668–674. doi:10.1038/nrmicro2387 PubMedPubMedCentral

23.

Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF et al (2011) MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 121:1827–1833. doi:10.1172/JCI45666 PubMedPubMedCentralCrossRef

24.

Elkington PTG, Nuttall RK, Boyle JJ, O’Kane CM, Horncastle DE, Edwards DR et al (2005) Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 172:1596–1604. doi:10.1164/rccm.200505-753OC PubMedCrossRef

25.

Elkington PT, Ugarte-Gil CA, Friedland JS (2011) Matrix metalloproteinases in tuberculosis. Eur Respir J 38:456–464. doi:10.1183/09031936.00015411 PubMedCrossRef

26.

Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561–572PubMedCrossRef

27.

Blomgran R, Ernst JD (2011) Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 186:7110–7119. doi:10.4049/jimmunol.1100001 PubMedPubMedCentralCrossRef

28.

Majlessi L, Prados-Rosales R, Casadevall A, Brosch R (2015) Release of mycobacterial antigens. Immunol Rev 264:25–45. doi:10.1111/imr.12251 PubMedCrossRef

29.

Bottai D, Brosch R (2009) Mycobacterial PE, PPE and ESX clusters: novel insights into the secretion of these most unusual protein families. Mol Microbiol 73:325–328. doi:10.1111/j.1365-2958.2009.06784.x PubMedCrossRef

30.

Gey van Pittius NC, Sampson SL, Lee H, Kim Y, van Helden PD, Warren RM (2006) Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 6:95. doi:10.1186/1471-2148-6-95 PubMedPubMedCentralCrossRef

31.

Daleke MH, Cascioferro A, de Punder K, Ummels R, Abdallah AM, van der Wel N et al (2011) Conserved Pro-Glu (PE) and Pro-Pro-Glu (PPE) protein domains target LipY lipases of pathogenic mycobacteria to the cell surface via the ESX-5 pathway. J Biol Chem 286:19024–19034. doi:10.1074/jbc.M110.204966 PubMedPubMedCentralCrossRef

32.

[No authors listed] (1999) Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis research centre (ICMR), Chennai. Indian J Med Res 110:56–69

33.

Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698–702PubMedCrossRef

34.

Black GF, Dockrell HM, Crampin AC, Floyd S, Weir RE, Bliss L et al (2001) Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis 184:322–329. doi:10.1086/322042 PubMedCrossRef

35.

Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–1345PubMedCrossRef

36.

Bastos RG, Borsuk S, Seixas FK, Dellagostin OA (2009) Recombinant Mycobacterium bovis BCG. Vaccine 27:6495–6503. doi:10.1016/j.vaccine.2009.08.044 PubMedCrossRef

37.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic’ S (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97:13853–13858. doi:10.1073/pnas.250480397 PubMedPubMedCentralCrossRef

38.

Wangoo A, Brown IN, Marshall BG, Cook HT, Young DB, Shaw RJ (2000) Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin Exp Immunol 119:92–98PubMedPubMedCentralCrossRef

39.

Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci U S A 93:934–939PubMedPubMedCentralCrossRef

40.

Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK et al (2011) Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice. Vaccine 29:4754–4760. doi:10.1016/j.vaccine.2011.04.086 PubMedCrossRef

41.

Behr MA (2002) BCG—different strains, different vaccines? Lancet Infect Dis 2:86–92PubMedCrossRef

42.

Behr MA, Small PM (1997) Has BCG attenuated to impotence? Nature 389:133–134. doi:10.1038/38151 PubMedCrossRef

43.

Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST (1999) Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32:643–655PubMedCrossRef

44.

Jungblut PR, Schaible UE, Mollenkopf HJ, Zimny-Arndt U, Raupach B, Mattow J et al (1999) Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 33:1103–1117PubMedCrossRef

45.

Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178:1274–1282PubMedPubMedCentral

46.

Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A et al (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9:533–539. doi:10.1038/nm859 PubMedCrossRef

47.

Kaufmann SHE, Baumann S, Nasser Eddine A (2006) Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 10:1068–1079PubMed

48.

Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69:2773–2778. doi:10.1128/IAI.69.5.2773-2778.2001 PubMedCrossRef

49.

Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171:1602–1609PubMedCrossRef

50.

Agger EM, Andersen P (2002) A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 21:7–14PubMedCrossRef

51.

Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115:2472–2479. doi:10.1172/JCI24617 PubMedPubMedCentralCrossRef

52.

Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SHE (2011) Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204:1573–1584. doi:10.1093/infdis/jir592 PubMedPubMedCentralCrossRef

53.

Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP et al (1997) Differential effects of cytolytic T cell subsets on intracellular infection. Science 276:1684–1687PubMedCrossRef

54.

Cho S, Mehra V, Thoma-Uszynski S, Stenger S, Serbina N, Mazzaccaro RJ et al (2000) Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A 97:12210–12215. doi:10.1073/pnas.210391497 PubMedPubMedCentralCrossRef

55.

Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 89:12013–12017PubMedPubMedCentralCrossRef

56.

Britton WJ, Palendira U (2003) Improving vaccines against tuberculosis. Immunol Cell Biol 81:34–45. doi:10.1046/j.0818-9641.2002.01143.x PubMedCrossRef

57.

Fine PE (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11(Suppl 2):S353–S359PubMedCrossRef

58.

Palmer CE, Long MW (1966) Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 94:553–568PubMed

59.

Rook GA, Bahr GM, Stanford JL (1981) The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 62:63–68PubMedCrossRef

60.

Hernandez-Pando R, Pavön L, Arriaga K, Orozco H, Madrid-Marina V, Rook G (1997) Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 65:3317–3327PubMedPubMedCentral

61.

Seah GT, Scott GM, Rook GA (2000) Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181:385–389. doi:10.1086/315200 PubMedCrossRef

62.

Luo Y, Chen X, Han R, O’Donnell MA (2001) Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264–270PubMedPubMedCentralCrossRef

63.

Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P (1996) Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157:3527–3533PubMed

64.

Andersen P, Andersen AB, Sørensen AL, Nagai S (1995) Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 154:3359–3372PubMed

65.

Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS et al (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183:469–477. doi:10.1086/318081 PubMedCrossRef

66.

Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA et al (1999) Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179:637–645. doi:10.1086/314640 PubMedCrossRef

67.

Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ (1999) Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67:1702–1707PubMedPubMedCentral

68.

Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S (1999) Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 67:4780–4786PubMedPubMedCentral

69.

Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68:791–795PubMedPubMedCentralCrossRef

70.

Olsen AW, Hansen PR, Holm A, Andersen P (2000) Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30:1724–1732. doi:10.1002/1521-4141(200006)30:6<1724::AID-IMMU1724>3.0.CO;2-A PubMedCrossRef

71.

Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694. doi:10.1016/S0140-6736(98)07422-4 PubMedCrossRef

72.

O’Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA et al (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508–2514PubMedPubMedCentral

73.

Young SL, O’Donnell MA, Buchan GS (2002) IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. Int Immunol 14:793–800PubMedCrossRef

74.

Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C (2002) Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 70:6549–6557PubMedPubMedCentralCrossRef

75.

Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH et al (2008) A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198:1491–1501. doi:10.1086/592450 PubMedPubMedCentralCrossRef

76.

Dhar N, Rao V, Tyagi AK (2004) Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol 193:19–25. doi:10.1007/s00430-002-0170-x PubMedCrossRef

77.

Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T (2007) Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 87:518–525. doi:10.1016/j.tube.2007.06.002 CrossRef

78.

Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A et al (2009) Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine 27:28–37. doi:10.1016/j.vaccine.2008.10.034 PubMedCrossRef

79.

Qie YQ, Wang JL, Zhu BD, Xu Y, Wang QZ, Chen JZ et al (2008) Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice. Scand J Immunol 67:133–139. doi:10.1111/j.1365-3083.2007.02048.x PubMedCrossRef

80.

Tang C, Yamada H, Shibata K, Maeda N, Yoshida S, Wajjwalku W et al (2008) Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis. J Infect Dis 197:1263–1274. doi:10.1086/586902 PubMedCrossRef

81.

Lin C-W, Su I-J, Chang J-R, Chen Y-Y, Lu J-J, Dou H-Y (2012) Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice. APMIS 120:72–82. doi:10.1111/j.1600-0463.2011.02815.x PubMedCrossRef

82.

Chen Y-Y, Lin C-W, Huang W-F, Chang J-R, Su I-J, Hsu C-H et al (2014) Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis. J Microbiol Immunol Infect. doi:10.1016/j.jmii.2014.11.019

83.

Ahsan MJ (2015) Recent advances in the development of vaccines for tuberculosis. Ther Adv Vaccines 3:66–75. doi:10.1177/2051013615593891 PubMedPubMedCentralCrossRef

84.

Waters WR, Palmer MV, Buddle BM, Vordermeier HM (2012) Bovine tuberculosis vaccine research: historical perspectives and recent advances. Vaccine 30:2611–2622. doi:10.1016/j.vaccine.2012.02.018 PubMedCrossRef

85.

Buddle BM, Wedlock DN, Denis M, Vordermeier HM, Hewinson RG (2011) Update on vaccination of cattle and wildlife populations against tuberculosis. Vet Microbiol 151:14–22. doi:10.1016/j.vetmic.2011.02.021 PubMedCrossRef

86.

Hu X-D, Yu D-H, Chen S-T, Li S-X, Cai H (2009) A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle. DNA Cell Biol 28:191–199. doi:10.1089/dna.2008.0790 PubMedCrossRef

87.

Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T et al (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77:3364–3373. doi:10.1128/IAI.00287-09 PubMedPubMedCentralCrossRef

88.

Wedlock DN, Denis M, Painter GF, Ainge GD, Vordermeier HM, Hewinson RG et al (2008) Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clin Vaccine Immunol 15:765–772. doi:10.1128/CVI.00034-08 PubMedPubMedCentralCrossRef

89.

Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM et al (2005) Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect Immun 73:3540–3546. doi:10.1128/IAI.73.6.3540-3546.2005 PubMedPubMedCentralCrossRef

90.

Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V et al (2012) Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One 7, e51396. doi:10.1371/journal.pone.0051396 PubMedPubMedCentralCrossRef

91.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (2006) A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24:1593–1600. doi:10.1016/j.vaccine.2005.10.002 PubMedCrossRef

92.

Blanco FC, Bianco MV, Garbaccio S, Meikle V, Gravisaco MJ, Montenegro V et al (2013) Mycobacterium bovis Δmce2 double deletion mutant protects cattle against challenge with virulent M. bovis. Tuberculosis (Edinb) 93:363–372. doi:10.1016/j.tube.2013.02.004 CrossRef

93.

Khatri B, Whelan A, Clifford D, Petrera A, Sander P, Vordermeier HM (2014) BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine 32:779–784. doi:10.1016/j.vaccine.2013.12.055 PubMedCrossRef

94.

García E, Bianco MV, Gravisaco MJ, Rocha RV, Blanco FC, Bigi F (2015) Evaluation of Mycobacterium bovis double knockout mce2-phoP as candidate vaccine against bovine tuberculosis. Tuberculosis (Edinb) 95:186–189. doi:10.1016/j.tube.2015.01.001 CrossRef

95.

Tompkins DM, Ramsey DSL, Cross ML, Aldwell FE, de Lisle GW, Buddle BM (2009) Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums. Proc Biol Sci 276:2987–2995. doi:10.1098/rspb.2009.0414 PubMedPubMedCentralCrossRef

96.

Murphy D, Costello E, Aldwell FE, Lesellier S, Chambers MA, Fitzsimons T et al (2014) Oral vaccination of badgers (Meles meles) against tuberculosis: comparison of the protection generated by BCG vaccine strains Pasteur and Danish. Vet J 200:362–367. doi:10.1016/j.tvjl.2014.02.031 PubMedCrossRef

97.

Yeremeev VV, Stewart GR, Neyrolles O, Skrabal K, Avdienko VG, Apt AS et al (2000) Deletion of the 19kDa antigen does not alter the protective efficacy of BCG. Tuber Lung Dis 80:243–247. doi:10.1054/tuld.2000.0252 PubMedCrossRef

98.

Rao V, Dhar N, Shakila H, Singh R, Khera A, Jain R et al (2005) Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. Scand J Immunol 61:410–417. doi:10.1111/j.1365-3083.2005.01569.x PubMedCrossRef

99.

Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11:153–162. doi:10.1038/nrurol.2014.15 PubMedCrossRef

100.

Streit JA, Recker TJ, Donelson JE, Wilson ME (2000) BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 94:33–41. doi:10.1006/expr.1999.4459 PubMedCrossRef

101.

Varaldo PB, Leite LCC, Dias WO, Miyaji EN, Torres FIG, Gebara VC et al (2004) Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun 72:3336–3343. doi:10.1128/IAI.72.6.3336-3343.2004 PubMedPubMedCentralCrossRef

102.

Seixas FK, da Silva EF, Hartwig DD, Cerqueira GM, Amaral M, Fagundes MQ et al (2007) Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 26:88–95. doi:10.1016/j.vaccine.2007.10.052 PubMedCrossRef

103.

Govan VA, Christensen ND, Berkower C, Jacobs WR Jr, Williamson A-L (2006) Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24:2087–2093. doi:10.1016/j.vaccine.2005.11.029 PubMedCrossRef

Titel: Manipulation of BCG vaccine: a double-edged sword
verfasst von: V. K. Singh
R. Srivastava
B. S. Srivastava
Publikationsdatum: 25.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2016
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-016-2579-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Genotype-specific concordance of oral and genital human papillomavirus infections among marital couples is low

Individualized significance of the −251 A/T single nucleotide polymorphism of interleukin-8 in severe infections

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

Cytotoxic immune responses in the lungs correlate to disease severity in patients with hantavirus infection

Time to positivity of blood culture and its prognostic value in bloodstream infection